These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7911901)

  • 1. Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis.
    Davidson DC; Peart I; Turner S; Sangster M
    Lancet; 1994 Jun; 343(8912):1575. PubMed ID: 7911901
    [No Abstract]   [Full Text] [Related]  

  • 2. Anaphylactoid reactions and bradykinin generation in patients treated with LDL-apheresis and an ACE inhibitor.
    Koga N; Nagano T; Sato T; Kagasawa K
    ASAIO J; 1993; 39(3):M288-91. PubMed ID: 8268545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin receptor antagonists during dextran sulfate LDL-apheresis are safe.
    Sinzinger H; Chehne F; Ferlitsch A; Oguogho A
    Thromb Res; 2000 Oct; 100(1):43-6. PubMed ID: 11053615
    [No Abstract]   [Full Text] [Related]  

  • 4. Anaphylactoid reactions during dextran apheresis may occur even in the absence of ACE-inhibitor administration.
    Schwarzbeck A; Hilgenfeldt U; Riester U; Rambausek M; Kiral A
    Nephrol Dial Transplant; 1997 May; 12(5):1083-4. PubMed ID: 9175084
    [No Abstract]   [Full Text] [Related]  

  • 5. Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis.
    Kojima S; Ogi M; Yoshitomi Y; Kuramochi M; Ikeda J; Naganawa M; Hatakeyama H
    Int J Artif Organs; 1997 Mar; 20(3):178-83. PubMed ID: 9151155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bradykinin-receptor antagonist icatibant: possible treatment for ACE inhibitor-related angio-oedema.
    Manders K; van Deuren M; Hoedemaekers C; Simon A
    Neth J Med; 2012 Oct; 70(8):386-7. PubMed ID: 23065991
    [No Abstract]   [Full Text] [Related]  

  • 7. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
    Bambauer R; Schneidewind JM; Latza R
    ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin.
    Krieter DH; Grude M; Lemke HD; Fink E; Bönner G; Schölkens BA; Schulz E; Müller GA
    Kidney Int; 1998 Apr; 53(4):1026-35. PubMed ID: 9551414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The apheresis of low-density lipoproteins in homozygous familial hypercholesterolemia].
    Ros Rahola E
    Med Clin (Barc); 1993 Jan; 100(3):117-8. PubMed ID: 8426494
    [No Abstract]   [Full Text] [Related]  

  • 10. Case report: Prevention of apheresis reactions with icatibant.
    Kirkpatrick CH; Pirzad A
    J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1734-1735. PubMed ID: 33181344
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes in lipoprotein profile after selective LDL apheresis.
    Matsunaga T; Takasaki S; Masakane I; Okazaki M; Tomoike H
    Intern Med; 2004 Aug; 43(8):760. PubMed ID: 15468983
    [No Abstract]   [Full Text] [Related]  

  • 12. [LDL-apheresis: current status].
    Stefanutti C; Vivenzio A; Lucani G; Di Giacomo S
    Clin Ter; 2001; 152(1):65-9. PubMed ID: 11382172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selenium deficiency in hypercholesterolaemic patients treated with LDL apheresis.
    Jaudon MC; Assogba U; Bourely B; Dairou F; Bruckert E; Delattre J
    Lancet; 1994 May; 343(8906):1160. PubMed ID: 7910247
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunosorptive apheresis of LDL.
    Borberg H; Gaczkowski A; Oette K; Stoffel W
    Prog Clin Biol Res; 1990; 337():163-7. PubMed ID: 2191310
    [No Abstract]   [Full Text] [Related]  

  • 15. [Apheresis of low-density lipids in the treatment of hereditary hypercholesterolemia].
    Konovalov GA; Kukharchuk VV; Sinitsin VV; Trakht IN; Adamova IIu
    Vutr Boles; 1989; 28(4):133-6. PubMed ID: 2596087
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column.
    Kojima S; Harada-Shiba M; Nomura S; Kimura G; Tsushima M; Kuramochi M; Yamamoto A; Omae T
    ASAIO Trans; 1991; 37(4):644-8. PubMed ID: 1768503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of complications and adverse effects of apheresis].
    Yamamoto A; Hatanaka K; Kojima S
    Nihon Rinsho; 1992 Jan; 50 Suppl():388-93. PubMed ID: 1578712
    [No Abstract]   [Full Text] [Related]  

  • 18. [LDL apheresis--an effective treatment of homozygous familial hypercholesterolemia].
    Kauppinen-Mäkelin R; Koivisto V; Virtanen KS; Taskinen MR; Miettinen T
    Duodecim; 1990; 106(21):1465-70. PubMed ID: 1364677
    [No Abstract]   [Full Text] [Related]  

  • 19. From plasma-exchange to LDL-apheresis: new developments in the treatment of familial hypercholesterolemia.
    Postiglione A; Gnasso A; Mastranzo P; Montefusco S; Motti C; Gallotta G; Cortese C; Scarpato N
    Beitr Infusionsther; 1988; 23():74-80. PubMed ID: 2484784
    [No Abstract]   [Full Text] [Related]  

  • 20. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks.
    Bouillet L; Boccon-Gibod I; Ponard D; Drouet C; Cesbron JY; Dumestre-Perard C; Monnier N; Lunardi J; Massot C; Gompel A
    Ann Allergy Asthma Immunol; 2009 Nov; 103(5):448. PubMed ID: 19927548
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.